$49.33 +0.72 (%) Cepheid Inc - NASDAQ

Aug. 27, 2015 | 04:00 PM

Partner Headlines

  1. Stocks Fall For Fourth Day On Global Growth Worries

    IBD | Jul. 24, 2015 | 16:21PM EST
  2. Major Indexes Extend Losses; Sucampo Bucks Weakness

    IBD | Jul. 24, 2015 | 15:01PM EST
  3. Morning Market Losers

    Benzinga | Jul. 24, 2015 | 09:55AM EST
  4. Stocks On Pace For Fourth Straight Gain; GoPro Gains

    IBD | Jul. 14, 2015 | 14:55PM EST
  5. Stocks Hold On To Most Gains; Biotechs Quicken Their Pulse

    IBD | Jul. 14, 2015 | 13:19PM EST
  6. Stocks Lower In Late Trading, But Utilities Rally

    IBD | Jul. 2, 2015 | 14:53PM EST
  7. Craig-Hallum Upgrades Cepheid To Buy

    Benzinga | Jun. 26, 2015 | 09:26AM EST
  8. Morning Market Gainers

    Benzinga | Apr. 24, 2015 | 09:42AM EST
  9. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga | Apr. 15, 2015 | 07:41AM EST
  10. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga | Feb. 13, 2015 | 15:32PM EST
  11. Leading Medical Stock Cepheid Trying To Break Out

    IBD | Jan. 14, 2015 | 18:20PM EST
  12. Benzinga's Top Upgrades

    Benzinga | Dec. 18, 2014 | 08:53AM EST
  13. Bank of America Upgrades Cepheid To Buy

    Benzinga | Dec. 18, 2014 | 08:08AM EST
  14. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga | Dec. 4, 2014 | 10:07AM EST
  15. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD | Dec. 2, 2014 | 17:48PM EST
  16. Cepheid Receives FDA Clearance For Xpert Norovirus, The First On-Demand Molecular Test For Detection of Norovirus

    Benzinga | Dec. 1, 2014 | 07:02AM EST
  17. CEPHEID

    IBD | Nov. 24, 2014 | 18:43PM EST
  18. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga | Nov. 24, 2014 | 16:05PM EST
  19. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga | Nov. 13, 2014 | 07:01AM EST
  20. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD | Nov. 6, 2014 | 18:41PM EST
  21. Stocks Fight Back To Finish Mixed

    IBD | Oct. 27, 2014 | 16:20PM EST
  22. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD | Oct. 27, 2014 | 15:00PM EST
  23. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD | Oct. 17, 2014 | 16:31PM EST
  24. CEPHEID

    IBD | Oct. 16, 2014 | 18:49PM EST
  25. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga | Oct. 1, 2014 | 16:06PM EST
  26. UPDATE: ISI Group Upgrades Cepheid

    Benzinga | Aug. 11, 2014 | 15:47PM EST
  27. CEPHEID

    IBD | Jul. 17, 2014 | 18:49PM EST
  28. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD | Feb. 4, 2014 | 18:42PM EST
  29. Alexion Takes Off On Outlook

    IBD | Jan. 30, 2014 | 18:52PM EST
  30. Three Medical Tech Names To Watch In Healthcare Space

    IBD | Jan. 3, 2014 | 18:22PM EST
  31. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD | Dec. 23, 2013 | 16:45PM EST
  32. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market Leader Position

    Benzinga | Dec. 18, 2013 | 09:34AM EST
  33. Five Medical Stocks Leaders Trade Near New Highs

    IBD | Nov. 22, 2013 | 18:49PM EST
  34. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD | Nov. 11, 2013 | 17:13PM EST
  35. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining Revenue Multiple

    Benzinga | Oct. 4, 2013 | 11:53AM EST
  36. Benzinga's Top Downgrades

    Benzinga | Oct. 4, 2013 | 07:34AM EST
  37. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga | Oct. 1, 2013 | 08:54AM EST
  38. Benzinga's Top Downgrades

    Benzinga | Oct. 1, 2013 | 08:17AM EST
  39. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' by FDA

    Benzinga | Aug. 28, 2013 | 07:04AM EST
  40. Cepheid Announces Board of Directors Changes

    Benzinga | Feb. 14, 2013 | 09:09AM EST
  41. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate Complexity' by FDA

    Benzinga | Jan. 15, 2013 | 00:13AM EST
  42. Medtech Stocks Moving As Conference Makes Waves

    IBD | Jan. 8, 2013 | 07:25AM EST
  43. Medtech Stocks Moving As Conference Makes Waves

    IBD | Jan. 8, 2013 | 07:21AM EST
  44. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ~$92M vs $93.5M Est, EPS $0.10-0.12

    Benzinga | Jan. 8, 2013 | 01:36AM EST
  45. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga | Jan. 4, 2013 | 03:15AM EST
  46. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:46AM EST
  47. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:44AM EST
  48. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga | Dec. 28, 2012 | 03:44AM EST
  49. US Stock Futures Down Ahead Of Economic Data

    Benzinga | Dec. 27, 2012 | 23:18PM EST
  50. Stocks To Watch For December 28, 2012

    Benzinga | Dec. 27, 2012 | 18:42PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!